Vol 76, No 2 (2018)
Original articles
Published online: 2017-10-27

open access

Page views 707
Article views/downloads 427
Get Citation

Connect on Social Media

Connect on Social Media

Nesfatin-1 levels in patients with slow coronary flow

Mevlüt Serdar Kuyumcu, Aliye Kuyumcu1, Çağrı Yayla2, Mustafa Bilal Özbay2, Mehmet Alagöz3, Sefa Ünal2, Burak Açar2, Özcan Özeke2, Gülhan Samur4
Kardiol Pol 2018;76(2):401-405.

Abstract

Background: Nesfatin-1 is a novel anorectic neuropeptide with potent metabolic regulatory effects.

Aim: We aimed to evaluate the relationship between nesfatin-1 levels and slow coronary flow (SCF).

Methods: A total of 60 consecutive patients with SCF and 60 consecutive patients with normal coronary flow (NCF) were enrolled into the study. Nesfatin-1 level was measured from blood serum samples using enzyme-linked immunosorbent assay test.

Results: Serum nesfatin-1 levels were significantly lower in the SCF group compared to the NCF group (p < 0.001). Low levels of nesfatin-1 were found to be significantly and independently associated with the SCF (odds ratio 0.982, 95% confidence interval 0.969–0.995, p = 0.005).

Conclusions: The results of this study showed that serum nesfatin-1 level was lower in the SCF group than in the NCF group. Nesfatin-1 could play a role in the pathogenesis of SCF phenomenon with mechanisms such as inflammation and endothelial dysfunction. Further studies are needed to determine the relation between SCF and nesfatin-1.

Article available in PDF format

View PDF Download PDF file



Polish Heart Journal (Kardiologia Polska)